Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2023-11-17 Call Transcript
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an investor call held on November 15, 2023, discussing the company's quarterly performance for Q3 FY23 and nine months ended September 30, 2023. It includes detailed management commentary on financial results, operational updates, product launches, and a Q&A session with analysts. The presence of a full transcript of the call, including management introductions, financial discussions, and Q&A, clearly identifies this as a Call Transcript (CT). The document is about 15,000 characters long, contains substantive content, and is not merely an announcement or summary. Therefore, the appropriate classification is Call Transcript (CT).
2023-11-17 English
Please find enclosed herewith transcript of the Investors / Analysts Call scheduled on 15th November 2023. The same is also being uploaded on the website of the Company.
Call Transcript Classification · 100% confidence The document is a transcript of an investor call held on November 15, 2023, discussing the company's quarterly performance for Q3 FY23 and nine months ended September 30, 2023. It includes detailed management commentary on financial results, operational updates, product launches, and a Q&A session with investors and analysts. The presence of a full transcript of the call, including management introductions, financial discussions, and Q&A, clearly identifies this as a Call Transcript (CT). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice but the full transcript itself.
2023-11-17 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges disclosing information under Regulation 30 of SEBI (LODR) Regulations, 2015. It informs about a court order directing a meeting of shareholders and creditors to approve a scheme of arrangement (demerger) and mentions a joint application for rectification of an error in the order. The document is short (2220 characters) and serves as an announcement of a regulatory event related to corporate restructuring. It does not contain financial statements, detailed financial data, or the actual scheme document itself. It is an update on a corporate action and regulatory compliance disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-17 English
We would like to inform you that the company and the resulting company has filed a joint application before Hon''ble NCLT, Mumbai Bench, seeking rectification of an apparent error in the ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges disclosing information under Regulation 30 of SEBI (LODR) Regulations, 2015. It informs about a court order directing a meeting of shareholders and creditors to approve a scheme of arrangement (demerger) and mentions a joint application for rectification of an error in the order. The document is short (2220 characters) and serves as an announcement of a regulatory event related to corporate restructuring, not a full report or detailed financial disclosure. It does not contain financial statements or detailed analysis but is a regulatory disclosure about a corporate action. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-17 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Sanofi India Limited dated 16th November 2023, addressed to stock exchanges, enclosing the newspaper publication of financial results for the quarter and nine months ended 30th September 2023. The text includes an extract of standalone and consolidated unaudited financial results for the quarter and nine months ended 30th September 2023, with detailed financial figures such as total income, net profit before and after tax, and earnings per share. The results are unaudited and have been approved by the Board of Directors on 8th November 2023. The document is not a full annual report but a quarterly/periodical financial results announcement with substantive financial data and analysis. It is not merely an announcement of a report or a certification letter. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-11-16 English
Please find the enclosed copies of Newspaper publication of Financial Results for Quarter and Nine months ended 30th September 2023 of the company published on 10th November 2023, in Business ....
Interim / Quarterly Report Classification · 95% confidence The document is a newspaper publication of financial results for the quarter and nine months ended 30th September 2023 by Sanofi India Limited. It includes an extract of standalone and consolidated unaudited financial results with detailed financial figures such as total income, net profit before and after tax, and earnings per share. The document references compliance with Indian Accounting Standards and SEBI regulations, and it is signed by the Managing Director and Company Secretary. The content is a comprehensive financial report for a period shorter than a full fiscal year (quarter and nine months), containing actual financial statements and substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (13,661 characters) and detailed financial data confirm it is the report itself, not merely an announcement or certification. 9M 2023
2023-11-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.